Metrics as of 10/17/2026, 08:37 AM (Berlin time), refresh in progress.
SkinBioTherapeutics Stock
SkinBioTherapeutics Plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Rachel Lisa Parsonage
- Employees
- 41
- Market cap
- £16 M
- IPO
- 05/04/2017
SkinBioTherapeutics Plc is a life sciences enterprise dedicated to enhancing human health through the exploration and development of technologies that harness the power of the human microbiome. The company has developed two primary technological platforms: SkinBiotix: This innovative solution is designed to strengthen…
SkinBioTherapeutics stock: price history
1D
+4.3%
1W
+12.1%
1M
-35.1%
6M
-38.5%
YTD
-61.9%
1Y
-57.4%
2Y
-59.3%
5Y
-89.8%
10Y
–
Next earnings date
Next earnings date
02/12/2026 (in 46 days)
Volatility around earnings
~27% stronger price swings than usual
Ask the agents about SkinBioTherapeutics
SkinBioTherapeutics stock metrics
P/E
-33.33
P/B
1.95
EV/EBITDA
-134.62
RETURN ON EQUITY
-10.0%
NET MARGIN
-36.7%
DEBT/EQUITY
0.12
DIVIDEND YIELD
0.0%
AS OF
31/12/2025
Free float & liquidity
FREE FLOAT
80.6%
FLOAT SHARES
208,857,811
AVG. DAILY VOLUME (30D)
4,165,258
Comparable stocks
Frequently asked questions about SkinBioTherapeutics stock
What does SkinBioTherapeutics do?
SkinBioTherapeutics Plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Rachel Lisa Parsonage, the company employs around 41 people.
The IPO was on 05/04/2017; the stock trades on LSE under the ticker SBTX.L.
When does SkinBioTherapeutics report next?
The next earnings date is 02/12/2026.
Around past earnings, price swings were roughly 27% stronger than usual.
Does SkinBioTherapeutics pay a dividend?
No, SkinBioTherapeutics currently does not pay a dividend.
Which stocks are comparable to SkinBioTherapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get SkinBioTherapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess SkinBioTherapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.